Maternal serum alpha-fetoprotein screening: a cost-benefit analysis.
The prenatal detection of fetal neural tube defects (NTD) is now possible by means of a multi-tiered program utilizing maternal serum alpha-fetoprotein (MSAFP) screening coupled with ultrasonography and amniocentesis where indicated. This paper considers the economic consequences of screening for fetal NTD a theoretical cohort of 100,000 pregnant women at risk of having an affected fetus who would elect to terminate their pregnancies if an affected fetus were found. The cost of the program was balanced against the benefits of the program, such as the averted costs of institutionalization, medical care, and the like. The total cost of the program to screen 100,000 such women was calculated to be $2,047,780, or slightly over $20 per woman screened, while the total economic benefits exceeded $4,000,000.
D000649:Amniocentesis; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D008403:Mass Screening / Q000191:economics*; D009313:National Health Programs; D009436:Neural Tube Defects / Q000175:diagnosis* / Q000191:economics / Q000453:epidemiology; D011247:Pregnancy; D011296:Prenatal Diagnosis / Q000191:economics*; D012306:Risk; D014463:Ultrasonography; D006113:United Kingdom; D014481:United States; D000509:alpha-Fetoproteins / Q000032:analysis*
D000509:alpha-Fetoproteins